Weight gain associated with antidiabetic medications

Therapy

Volumn 8, Issue 2, 2011, Pages 113-120

  Provilus, Alfrede ^a   Abdallah, Marie ^b   McFarlane, Samy I ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

antidiabetic medications; insulin; sulfonylurea; thiazolidinedione; weight gain

Indexed keywords

ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; DAPAGLIFLOZIN; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA;

BODY WEIGHT; CALORIC RESTRICTION; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; EVENING DOSAGE; EXERCISE; GLYCEMIC CONTROL; HUMAN; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 79953242767     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.11.8     Document Type: Review

References (64)

1. Tremble JM, Donaldson D: Is continued weight gain inevitable in Type 2 diabetes mellitus? J. R. Soc. Health 119, 235-239 (1999).
2. Karam JG, McFarlane SI: Update on the Prevention of Type 2 Diabetes. Curr. Diab. Rep. 11, 56-63 (2011).
3. McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J. Clin. Endocrinol. Metab. 86, 713-718 (2001).
4. Castro JP, El-Atat FA, McFarlane SI, Aneja A, Sowers JR: Cardiometabolic syndrome: pathophysiology and treatment. Curr. Hypertens. Rep. 5, 393-401 (2003).
5. Ridderstrale M, Gudbjornsdottir S, Eliasson B, Nilsson PM, Cederholm J: Obesity and cardiovascular risk factors in Type 2 diabetes: results from the Swedish National Diabetes Register. J. Intern. Med. 259, 314-322 (2006).
6. McFarlane SI, Castro J, Kaur J et al.: Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared with men. J. Clin. Hypertens. 7, 73-80 (2005).
7. McFarlane SI, Jacober SJ, Winer N et al.: Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 25, 718-723 (2002).
8. Hermansen K, Mortensen LS: Bodyweight changes associated with antihyperglycaemic agents in Type 2 diabetes mellitus. Drug Safe. 30, 1127-1142 (2007).
9. Willett WC, Manson JE, Stampfer MJ et al.: Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA 273, 461-465 (1995).
10. McFarlane SI: Antidiabetic medications and weight gain: implications for the practicing physician. Curr. Diab. Rep. 9, 249-254 (2009).
11. McFarlane SI: Insulin therapy and Type 2 diabetes: management of weight gain. J. Clin. Hypertens. 11, 601-607 (2009). The use of basal insulin analogs may offer advantages over conventional human insulin preparations in terms of more physiologic time-action profiles, reduced risk of hypoglycemia and reduced weight gain.
12. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 352, 837-853 (1998).
13. Farag A, Karam J, Nicasio J, McFarlane SI: Prevention of Type 2 diabetes: an update. Curr. Diab. Rep. 7, 200-207 (2007).
14. Muniyappa R, El-Atat F, Aneja A, McFarlane SI: The Diabetes Prevention Program. Curr. Diab. Rep. 3, 221-222 (2003).
15. Lindstrom J, Peltonen M, Tuomilehto J: Lifestyle strategies for weight control: experience from the Finnish Diabetes Prevention Study. Proc. Nutr. Soc. 64, 81-88 (2005).
16. Molitch ME, Fujimoto W, Hamman RF, Knowler WC: The Diabetes Prevention Program and its global implications. J. Am. Soc. Nephrol. 14, S103-S107 (2003).
17. McBride PE, Einerson JA, Grant H et al.: Putting the Diabetes Prevention Program into practice: a program for weight loss and cardiovascular risk reduction for patients with metabolic syndrome or Type 2 diabetes mellitus. J. Nutr. Health Aging 12, 745S-749S (2008).
18. Klein S, Sheard NF, Pi-Sunyer X et al.: Weight management through lifestyle modification for the prevention and management of Type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 27, 2067-2073 (2004).
19. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R, Bergman RN: Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 17, 30-36 (1994).
20. Arora SK, McFarlane SI: The case for low carbohydrate diets in diabetes management. Nutr. Metab. 2, 16 (2005).
21. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T: Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 23, 1499-1504 (2000).
22. Lebovitz HE: Oral hypoglycemic agents. Prim. Care 15, 353-369 (1988).
23. Schernthaner G, Grimaldi A, Di Mario U et al.: GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in Type 2 diabetic patients. Eur. J. Clin. Invest. 34, 535-542 (2004).
24. Rosenstock J, Hassman DR, Madder RD et al.: Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 27, 1265-1270 (2004).
25. Malone M: Medications associated with weight gain. Ann. Pharmacother. 39(12), 2046-2055 (2005). Reviews weight gain and its possible mechanisms in the most commonly prescribed antidiabetic medications.
26. Spiegelman BM: PPAR-g: adipogenic regulator and thiazolidinedione receptor. Diabetes 47, 507-514 (1998).
27. Arner P: The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol. Metab. 14, 137-145 (2003).
28. Wilding J: Thiazolidinediones, insulin resistance and obesity: finding a balance. Int. J. Clin. Pract. 60, 1272-1280 (2006). Discusses the balance between the cardiovascular risks associated with weight gain and the weight gain associated with the use of antidiabetic medication.
29. Dormandy JA, Charbonnel B, Eckland DJ et al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279-1289 (2005).
30. Kahn SE, Haffner SM, Heise MA et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427-2443 (2006).
31. Gerstein HC, Yusuf S, Bosch J et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368, 1096-1105 (2006).
32. McFarlane SI, Provilus A, Shin JJ: Diabetes prevention between RAAS inhibition and PPAR-γ stimulation: the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. J. Cardiometab. Syndr. 2, 149-150 (2007).
33. Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN: How safe is the use of thiazolidinediones in clinical practice? Expert Opin. Drug Saf. 8(1), 15-32 (2009).
34. Bailey SD, Xie C, Do R et al.: Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. Diabetes Care 33, 2250-2253 (2010). Discusses thiazolidinedione-induced peripheral edema and congestive heart failure shedding light on genetic etiology (the role of the NFATC2 locus).
35. Hermansen K, Mortensen LS: Bodyweight changes associated with antihyperglycaemic agents in Type 2 diabetes mellitus. Drug Safe. 30, 1127-1142 (2007).
36. UK Prospective Diabetes Study Group: UK Prospective Diabetes Study 16. Overview of 6 years' therapy of Type II diabetes: a progressive disease. Diabetes 44, 1249-1258 (1995).
37. Nichols GA, Koo YH, Shah SN: Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J. Gen. Intern. Med. 22, 453-458 (2007).
38. Peyrot M, Rubin RR, Lauritzen T et al.: Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28, 2673-2679 (2005).
39. Carver C: Insulin treatment and the problem of weight gain in Type 2 diabetes. Diabetes Educ. 32, 910-917 (2006).
40. Goudswaard AN, Furlong NJ, Rutten GE, Stolk RP, Valk GD: Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with Type 2 diabetes mellitus. Cochrane Database Syst. Rev. CD003418 (2004). Demonstrates the effect of addition of metformin to insulin and other oral hypoglycemic drugs on weight gain and associated glycemic control.
41. Heller S: Weight gain during insulin therapy in patients with Type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 65(Suppl. 1), S23-S27 (2004).
42. Meneghini L: Why and how to use insulin therapy earlier in the management of Type 2 diabetes. South. Med. J. 100, 164-174 (2007).
43. Hsia SH: Insulin glargine compared with NPH among insulin-naive, U.S. inner city, ethnic minority Type 2 diabetic patients. Diabetes Res. Clin. Pract. (2010) (Epub ahead of print).
44. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W: Lower withinsubject variability of fasting blood glucose and reduced weight gain with insulin detemir compared with NPH insulin in patients with Type 2 diabetes. Diabetes Obes. Metab. 7, 56-64 (2005).
45. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B: Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled Type 2 diabetes. Clin. Ther. 28, 1569-1581 (2006).
46. Hermansen K, Davies M: Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes. Metab. 9, 209-217 (2007).
47. Fakhoury W, Lockhart I, Kotchie RW, Aagren M, LeReun C: Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with Type-2 diabetes. Pharmacology 82, 156-163 (2008).
48. Hennige AM, Sartorius T, Tschritter O et al.: Tissue selectivity of insulin detemir action in vivo. Diabetologia 49, 1274-1282 (2006).
49. 1c.
50. Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann. Intern. Med. 137, 25-33 (2002).
51. Barnett A, Allsworth J, Jameson K, Mann R: A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr. Med. Res. Opin. 23, 1493-1507 (2007).
52. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352, 854-865 (1998).
53. Nathan DM, Buse JB, Davidson MB et al.: Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29, 1963-1972 (2006). Reviews the effect of weight gain and weight loss whether due to lifestyle changes or medication effect on the glycemic control and diabetic complications, such as cardiovascular disease.
54. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P: Efficacy and safety of pioglitazone versus metformin in patients with Type 2 diabetes mellitus: a double-blind, randomized trial. J. Clin. Endocrinol. Metab. 89, 6068-6076 (2004).
55. Mannucci E, Ognibene A, Cremasco F et al.: Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 24, 489-494 (2001).
56. Lindsay JR, Duffy NA, McKillop AM et al.: Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet. Med. 22, 654-657 (2005).
57. Lee A, Morley JE: Metformin decreases food consumption and induces weight loss in subjects with obesity with Type II noninsulin-dependent diabetes. Obes. Res. 6, 47-53 (1998).
58. Jose B, Tahrani AA, Piya MK, Barnett AH: Exenatide once weekly: clinical outcomes and patient satisfaction. Patient Prefer. Adher. 4, 313-324 (2010).
59. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M: Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50, 2530-2539 (2001).
60. Riddle MC, Henry RR, Poon TH et al.: Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with Type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab. Res. Rev. 22, 483-491 (2006).
61. Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C: Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 31, 1816-1823 (2008).
62. 1c in conjunction with weight loss in patients with Type 2 diabetes approaching glycaemic targets. Diabetes Obes. Metab. 5, 408-414 (2003).
63. Scheen AJ, Van Gaal LF: Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of Type 2 diabetes. Rev. Med. Liege 63, 105-109 (2008).
64. Hanefeld M, Forst T: Dapagliflozin, an SGLT2 inhibitor, for diabetes. Lancet 375(9733), 2196-2198 (2010).